Received Nov 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
inappropriate dose schedule of vaccine; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 63-year-old female patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received first dose on 29-SEP-2025). Concomitant products included COVID-19 vaccine. On 24-NOV-2025, the patient received the 2nd dose of Twinrix. On 24-NOV-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: inappropriate dose schedule of vaccine). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-NOV-2025 The patient had her first dose of Twinrix administered on the 3-dose schedule was 29-SEP-2025 and she received her second dose on 24-NOV-2025 (inappropriate schedule of vaccine administered). The patient stated that she scheduled her second dose later due to receiving a Covid shot, and she did not want to be vaccinated with two different vaccines at the same time. No further information was provided. The batch number was not provided, and we are unable to contact the reporter.
COVID-19 VACCINE